MVP方案治疗非小细胞肺癌的疗效观察

Mitomycin plus Vindesine and Cispltin in patients with Non small cell lung cancer

目的观察ＭＶＰ方案治疗非小细胞肺癌（ＮＳＣＬＣ）的治疗效果和毒性反应。方法４５例非小细胞肺癌患者使用ＭＶＰ（ＭＭＣ＋ＶＤＳ＋ＤＤＰ）方案治疗。结果４５例患者中２１例有效，有效率为４６７％。分析诸因素对疗效的影响发现病期早较病期晚疗效好。生活质量评估Ｋａｒｎｏｆｓｋｙ评分升高为６８９％。骨髓抑制为剂量限制性毒性，白细胞下降７５６％无其他严重毒副反应发生。结论ＭＶＰ方案是治疗非小细胞肺癌有效且可以耐受的方案。

Objective Observe the therapeutic effects and toxicity reaction of MVP regimen for the treatment of non small cell lung cancer(NSCLC). Methods 45 cases were treated with MVP (MMC+VDS+DDP) regimen. Results Response rates were 46 7%(21/45).Neutropenia was the dose limited toxicity and was occurred in 75 6% of cases. No other serious side reaction occurred in all patients. Conclusions There was definitive good therapeutic effect but slight side reaction with MVP regimen in the treatment of NSCLC.